Insmed Incorporated (INSM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 10:50AM EDT. Market open.
| Previous Close | 55.94 |
| Open | 56.05 |
| Bid | 40.36 x 200 |
| Ask | 70.57 x 200 |
| Day's Range | 54.74 - 56.45 |
| 52 Week Range | 18.77 - 58.82 |
| Volume | |
| Avg. Volume | 2,867,425 |
| Market Cap | 9.082B |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
Data from a late-stage study shows that treatment with Insmed's (INSM) brensocatib reduced episodes of worsening disease symptoms in patients with bronchiectasis, a chronic lung condition.
- Investing.com
Insmed PT Raised to $67 at TD Cowen
TD Cowen analysts raised the price target on Insmed (NASDAQ:INSM) to $67.00 (from $45.00) while maintaining a Buy rating.
- Investor's Business Daily
The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease.
Insmed stock catapulted Tuesday after the biotech company's experimental lung disease treatment succeeded in a final-phase study.
© 2024 Yahoo. All rights reserved.